Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
57
257.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| TW |
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
261.3B TWD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
| Min | -21 347.1% |
| 30th Percentile | 0.7% |
| Median | 5% |
| 70th Percentile | 11.5% |
| Max | 698% |
Other Profitability Ratios
Caliway Biopharmaceuticals Co Ltd
Glance View
Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Caliway Biopharmaceuticals Co Ltd is -2 045%, which is below its 3-year median of -1 740.3%.
Over the last 3 years, Caliway Biopharmaceuticals Co Ltd’s Operating Margin has increased from -2 493.2% to -2 045%. During this period, it reached a low of -2 493.2% on Dec 1, 2022 and a high of -1 318.9% on Dec 31, 2023.